TOP BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES SECRETS

In Segment C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Contributors will obtain treatment right up until illness progression or perhaps the participants are not able to tolerate the study drugs.- "Our study exposed the important purpose with the KLF16/MYC regulatory axis in